X4 Pharmaceuticals has gained approval for its first product, XOLREMDI (mavorixafor), marking its entrance into the commercial rare disease market. The FDA approved mavorixafor on April 29, 2024, specifically for patients aged 12 and above diagnosed with WHIM syndrome (characterized by warts, hypogammaglobulinemia, infections, and myelokathexis). XOLREMDI’s approval signifies the end of a ten-year voyage for X4, which emerged in 2015 after acquiring mavorixafor, previously identified as X4P-001, from Sanofi.
X4 has set the cost of XOLREMDI at approximately $496,000 annually for patients weighing over 50 kilograms, and roughly $372,000 for those weighing 50 kilogram...
